Colorectal Cancer Screening Recommendations
Average-Risk Adults: Start Age and Primary Screening Options
Begin colorectal cancer screening at age 45 years for all average-risk adults, using either colonoscopy every 10 years or annual fecal immunochemical test (FIT) as first-tier options. 1
- The USPSTF assigns a Grade A recommendation (high certainty of substantial benefit) for screening ages 50-75 years, and a Grade B recommendation (moderate certainty of moderate benefit) for ages 45-49 years. 1
- The U.S. Multi-Society Task Force and American Cancer Society both support starting at age 45, though they acknowledge the evidence is stronger for age 50 and older. 1, 2
- Colonoscopy every 10 years and annual FIT are the only tier-1 screening tests with proven mortality reduction in randomized trials or strong modeling evidence. 2, 1, 3
Second-Tier Screening Options (Acceptable Alternatives)
- CT colonography every 5 years 1, 4
- FIT-DNA (multitarget stool DNA) every 3 years 1, 2
- Flexible sigmoidoscopy every 5-10 years, ideally combined with FIT every 2 years 1, 3
Tests NOT Recommended
- Serum tests (including Septin9 and Shield blood tests) lack evidence for mortality benefit and should not be used. 5, 2, 3
- Capsule endoscopy and urine-based tests are not endorsed due to insufficient evidence. 3
- Barium enema is no longer recommended. 4
When to Stop Screening
Stop screening at age 75 years in adults who are up-to-date with prior negative screening, particularly if they have had a high-quality colonoscopy. 1
- For ages 76-85 years, screening should be individualized based on:
- Discontinue screening after age 85 years regardless of prior history, as harms outweigh benefits. 1
- Stop screening at any age if life expectancy is <10 years due to comorbidities. 1, 3
Family History: When to Screen Earlier and More Intensively
High-Risk Family History (Requires Colonoscopy Every 5 Years)
Begin colonoscopy at age 40 years OR 10 years before the youngest affected relative's diagnosis (whichever is earlier), and repeat every 5 years, if: 1, 7, 2
- One first-degree relative diagnosed with colorectal cancer or advanced adenoma before age 60, OR
- Two or more first-degree relatives diagnosed at any age 1, 7, 2
Modest-Risk Family History (Average-Risk Screening Starting Earlier)
Begin average-risk screening options (colonoscopy every 10 years OR annual FIT) at age 40 years if: 7, 2
- One first-degree relative diagnosed with colorectal cancer or advanced adenoma at age 60 or older 7, 2
- This confers only 1.8-1.9 times increased risk and does not warrant intensive surveillance. 7
Critical Verification Step
- Confirm the exact relationship (first- vs. second-degree), age at diagnosis, and actual diagnosis (colorectal cancer vs. other cancers) through medical records, as family history is frequently inaccurate. 7
Personal History of Polyps: Surveillance Intervals
Low-Risk Adenomas
Repeat colonoscopy in 5-10 years if the initial exam showed: 1
- 1-2 small (<10 mm) tubular adenomas with low-grade dysplasia
- Complete removal was achieved 1
High-Risk Adenomas
Repeat colonoscopy in 3 years if: 1
- 3-10 adenomas, OR
- Any adenoma ≥10 mm, OR
- Any adenoma with villous features or high-grade dysplasia 1
- If the 3-year follow-up shows only 1-2 small tubular adenomas with low-grade dysplasia, extend the next interval to 5 years. 1
Very High-Risk Findings
Repeat colonoscopy in 2-6 months to verify complete removal if: 1
- Sessile adenomas removed piecemeal 1
Consider genetic evaluation if: 1
- ≥10 adenomas on a single exam (suspect familial adenomatous polyposis) 1
Hyperplastic Polyps
Return to average-risk screening intervals if only small rectal hyperplastic polyps were found (unless hyperplastic polyposis syndrome is suspected). 1
Inflammatory Bowel Disease: Surveillance Colonoscopy
Begin surveillance colonoscopy 8 years after onset of pancolitis OR 12-15 years after onset of left-sided colitis, and repeat every 1-2 years. 1
- These patients require colonoscopic surveillance, not stool-based screening. 4
- Chronic ulcerative colitis and Crohn's disease affecting the colon both qualify. 1
Hereditary Syndromes: Intensive Surveillance Protocols
Familial Adenomatous Polyposis (FAP)
Begin colonoscopy or flexible sigmoidoscopy at age 10-12 years and repeat annually until age 24, then adjust intervals based on age: 4
| Age Range | Interval |
|---|---|
| 10-24 years | Every 12 months |
| 24-34 years | Every 2 years |
| 34-44 years | Every 3 years |
| ≥44 years | Every 3-5 years |
- APC gene testing should be performed in at-risk first-degree relatives when a familial mutation is known. 4
- If APC testing is negative, follow average-risk screening. 4
- For attenuated FAP, begin colonoscopy at age 20 and repeat every 5 years. 4
- Consider MUTYH testing if polyposis is present but APC is negative. 4
Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome/HNPCC)
Begin colonoscopy at age 20-25 years OR 10 years before the youngest affected relative's diagnosis, and repeat every 1-2 years. 1
- Genetic counseling and testing are essential for at-risk family members. 1
Quality Indicators for Effective Colonoscopy
Ensure the endoscopist meets these benchmarks to maximize screening effectiveness: 7
- Adenoma detection rate ≥25% in men 7
- Cecal intubation rate >90% 7
- Withdrawal time ≥6 minutes 7
- Adequate bowel preparation is mandatory; discuss preparation protocols with patients before the procedure. 1, 4
Critical Pitfalls to Avoid
- Never use screening tests in symptomatic patients with rectal bleeding, unexplained weight loss, change in bowel habits, or narrowed stools—these require immediate diagnostic colonoscopy regardless of age or screening history. 5
- Do not screen if life expectancy is <10 years due to comorbidities, as screening will not provide benefit. 1, 3
- All positive stool-based tests require follow-up colonoscopy—failure to complete diagnostic workup renders screening ineffective. 5, 2
- Do not continue screening past age 75 in patients with adequate prior negative screening, as harms increasingly outweigh benefits. 5, 3
- Do not use blood-based tests (Septin9, Shield) as they lack guideline endorsement and mortality benefit evidence. 5, 2, 3